Research progress of N1-methyladenosine RNA modification in cancer DOI Creative Commons
Yafeng Liu, Shujun Zhang, Xiaohui Gao

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 30, 2024

Abstract N1-methyladenosine (m1A) is a post-transcriptionally modified RNA molecule that plays pivotal role in the regulation of various biological functions and activities. Especially cancer cell invasion, proliferation cycle regulation. Over recent years, there has been burgeoning interest investigating m1A modification RNA. Most studies have focused on enrichment areas different regions. This review provides comprehensive overview methodologies employed for detection modification. Furthermore, this delves into key players modification, known as “writers,” “erasers,” “readers.” by methyltransferases, or writers, such TRMT6, TRMT61A, TRMT61B, TRMT10C, NML, and, removed demethylases, erasers, including FTO ALKBH1, ALKBH3. It recognized m1A-binding proteins YTHDF1, TYHDF2, TYHDF3, TYHDC1, also “readers”. Additionally, we explore intricate relationship between its regulators their implications development progression specific types cancer, discuss how can potentially facilitate discovery novel approaches diagnosis, treatment, prognosis. Our summary methylated adenosine methods regulatory mechanisms cancers useful insights

Language: Английский

RNA modifications: importance in immune cell biology and related diseases DOI Creative Commons
Lian Cui, Rui Ma,

Jiangluyi Cai

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Sept. 22, 2022

RNA modifications have become hot topics recently. By influencing processes, including generation, transportation, function, and metabolization, they act as critical regulators of cell biology. The immune abnormality in human diseases is also a research focus progressing rapidly these years. Studies demonstrated that participate the multiple biological processes cells, development, differentiation, activation, migration, polarization, thereby modulating responses are involved some related diseases. In this review, we present existing knowledge functions underlying mechanisms modifications, N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), N4-acetylcytosine (ac4C), pseudouridine (Ψ), uridylation, adenosine-to-inosine (A-to-I) editing, summarize their roles Via regulating can pathogenesis diseases, such cancers, infection, inflammatory autoimmune We further highlight challenges future directions based on knowledge. All all, review will provide helpful well novel ideas for researchers area.

Language: Английский

Citations

197
Epigenetic modification of m6A regulator proteins in cancer DOI Creative Commons
Yumin Wang, Yan Wang, Harsh Patel

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: June 30, 2023

Divergent N6-methyladenosine (m6A) modifications are dynamic and reversible posttranscriptional RNA that mediated by m6A regulators or methylation regulators, i.e., methyltransferases ("writers"), demethylases ("erasers"), m6A-binding proteins ("readers"). Aberrant associated with cancer occurrence, development, progression, prognosis. Numerous studies have established aberrant function as either tumor suppressors oncogenes in multiple types. However, the functions mechanisms of remain largely elusive should be explored. Emerging suggest can modulated epigenetic modifications, namely, ubiquitination, SUMOylation, acetylation, methylation, phosphorylation, O-GlcNAcylation, ISGylation, lactylation via noncoding action, cancer. This review summarizes current roles The for modification genesis segregated. will improve understanding regulatory regulators.

Language: Английский

Citations

83
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance DOI Creative Commons
Hong Lin, Di Wang, Pinghan Wang

et al.

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: July 18, 2022

Abstract The resistance of tumor cells to therapy severely impairs the efficacy treatment, leading recurrence and metastasis various cancers. Clarifying underlying mechanisms therapeutic may provide new strategies for overcoming cancer resistance. N6-methyladenosine (m6A) is most prevalent RNA modification in eukaryotes, involved regulation splicing, translation, transport, degradation, stability processing, thus affecting several physiological processes progression. As a novel type multifunctional non-coding RNAs (ncRNAs), circular (circRNAs) have been demonstrated play vital roles anticancer therapy. Currently, accumulating studies revealed mutual m6A circRNAs, their interaction can further influence sensitivity treatment. In this review, we mainly summarized recent advances circRNAs modulation resistance, as well interplay potential mechanisms, providing promising insights future directions reversal cancer.

Language: Английский

Citations

81
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer DOI Creative Commons

Xueqi Ou,

Yeru Tan, Jindong Xie

et al.

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 73, P. 101063 - 101063

Published: Feb. 1, 2024

This study aims to explore the function and mechanism of G Protein-coupled receptor class C group 5 member A (GPRC5A) in docetaxel-resistance liver metastasis breast cancer.

Language: Английский

Citations

81
N6-methyladenosine-mediated gene regulation and therapeutic implications DOI
Yujiao Liu, Dan Yang, Tao Liu

et al.

Trends in Molecular Medicine, Journal Year: 2023, Volume and Issue: 29(6), P. 454 - 467

Published: April 15, 2023

Language: Английский

Citations

60
m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion DOI Creative Commons
Xiaoxue Cao,

Qishun Geng,

Danping Fan

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: March 1, 2023

Abstract N6-methyladenosine (m 6 A) methylation is the most universal internal modification in eukaryotic mRNA. With elaborate functions executed by m A writers, erasers, and readers, modulation involved myriad physiological pathological processes. Extensive studies have demonstrated diverse tumours, with effects on tumorigenesis, metastasis, resistance. Recent evidence has revealed an emerging role of tumour immunoregulation, divergent patterns been microenvironment. To depict regulatory immune microenvironment (TIME) its effect evasion, this review focuses TIME, which characterized hypoxia, metabolic reprogramming, acidity, immunosuppression, outlines A-regulated TIME evasion under stimuli. Furthermore, anti-tumour cells are summarized.

Language: Английский

Citations

56
Crosstalk between m6A modification and alternative splicing during cancer progression DOI Creative Commons

Zhi‐Man Zhu,

Fu‐Chun Huo, Jian Zhang

et al.

Clinical and Translational Medicine, Journal Year: 2023, Volume and Issue: 13(10)

Published: Oct. 1, 2023

Background N6-methyladenosine (m6A), the most prevalent internal mRNA modification in eukaryotes, is added by m6A methyltransferases, removed demethylases and recognised m6A-binding proteins. This significantly influences carious facets of RNA metabolism plays a pivotal role cellular physiological processes. Main body Pre-mRNA alternative splicing, process that generates multiple splice isoforms from multi-exon genes, contributes to protein diversity mammals. Moreover, presence crosstalk between with modifications on pre-mRNAs exerting regulatory control, has been established. The modulates splicing patterns recruiting specific RNA-binding proteins (RBPs) regulate or directly influencing interaction RBPs their target RNAs. Conversely, can impact deposition recognition mRNAs. integration expanded scope therapeutic strategies for cancer treatment, while offers novel insights into mechanistic methylation initiation progression. Conclusion review aims highlight biological functions machinery its implications tumourigenesis. Furthermore, we discuss clinical relevance understanding m6A-dependent tumour therapies.

Language: Английский

Citations

44
Metabolic Recoding of NSUN2‐Mediated m5C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m5C‐ENO1 Positive Feedback Loop DOI Creative Commons
Baoxiang Chen,

Yanrong Deng,

Yuntian Hong

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(28)

Published: May 20, 2024

The RNA modification, 5-methylcytosine (m

Language: Английский

Citations

27
YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis DOI Creative Commons
Jingyuan Wen, Xue Lin, Wei Yi

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(13)

Published: Jan. 21, 2024

Abstract N6‐methyladenosine (m 6 A) modification orchestrates cancer formation and progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma (HCC), immune evasion angiogenesis are characteristic features of its TME. The role YTH RNA binding protein 2 (YTHDF2), as an m A reader, in regulating HCC TME not fully understood. Herein, it is discovered that trimethylated histone H3 lysine 4 27 acetylation promoter region YTHDF2 enhanced expression HCC, upregulated predicted a worse prognosis. Animal experiments demonstrated Ythdf2 depletion inhibited spontaneous formation, while overexpression promoted xenografted progression. Mechanistically, recognized 5′‐untranslational ETS variant transcription factor 5 (ETV5) mRNA recruited eukaryotic translation initiation 3 subunit B to facilitate translation. Elevated ETV5 induced programmed death ligand‐1 vascular endothelial growth A, thereby promoting angiogenesis. Targeting via small interference RNA‐containing aptamer/liposomes successfully both Together, this findings reveal potential application prognosis targeted treatment.

Language: Английский

Citations

26
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities DOI Creative Commons
Nanhao Yin, Xintong Li, Xuanwei Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: May 22, 2024

Abstract Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance toxicity still remain. Due the advancement of immuno-oncology, an increasing number novel immunoregulatory targets mechanisms are being revealed, with relevant therapies promising improve clinical immunotherapy in foreseeable future. Therefore, comprehending larger picture is important. In this review, we analyze summarize current landscape preclinical translational mechanistic research, drug development, trials that brought about next-generation pharmacological anti-cancer agents candidates beyond classical immune checkpoint inhibitors. Along further clarification immunobiology advances antibody engineering, targeting additional inhibitory checkpoints, including LAG-3, TIM-3, TIGIT, CD47, B7 family members becoming important part research discovery, as structurally functionally optimized agonists co-stimulatory molecules T cells. Exemplified bispecific cell engagers, newly emerging bi-specific multi-specific antibodies can provide considerable benefits. Next-generation also include epigenetic drugs cytokine-based therapeutics. Cell therapies, vaccines, oncolytic viruses not covered review. This comprehensive review might aid development fastest possible adoption effective immuno-oncology modalities for benefit patients.

Language: Английский

Citations

20